Climb Bio to Host Virtual Investor Event on October 15, 2024
Climb Bio (Nasdaq: CLYM) has announced a virtual investor event scheduled for October 15, 2024. The event will feature presentations from key management team members and an external expert, providing updates on the company's strategy and focus on developing therapeutics for immune-mediated diseases.
Presenters will include Aoife Brennan (President and CEO), Stephen Thomas (Board Member), Jan Hillson (Senior Clinical Advisor), Nishi Rampal (SVP of Clinical Development), Brett Kaplan (COO), and Frank Cortazar (Director of the New York Nephrology Vasculitis and Glomerular Center).
The event will offer an in-depth review of Climb Bio's lead asset, budoprutug, an anti-CD19 monoclonal antibody designed to treat various immune-mediated diseases. Budoprutug has shown B-cell depletion in early clinical trials. A live webcast and replay will be available on the company's website.
Climb Bio (Nasdaq: CLYM) ha annunciato un evento virtuale per gli investitori programmato per il 15 ottobre 2024. L'evento presenterà interventi da parte di membri chiave del team dirigenziale e di un esperto esterno, fornendo aggiornamenti sulla strategia dell'azienda e sull'attenzione allo sviluppo di terapie per malattie a mediazione immunitaria.
I presentatori includeranno Aoife Brennan (Presidente e CEO), Stephen Thomas (Membro del Consiglio), Jan Hillson (Consigliere Clinico Senior), Nishi Rampal (SVP dello Sviluppo Clinico), Brett Kaplan (COO) e Frank Cortazar (Direttore del Centro di Nefrologia Vasculite e Glomerulare di New York).
L'evento offrirà una revisione dettagliata del principale asset di Climb Bio, budoprutug, un anticorpo monoclonale anti-CD19 progettato per trattare diverse malattie a mediazione immunitaria. Budoprutug ha mostrato deplezione delle cellule B nei primi studi clinici. Una trasmissione in diretta e il replay saranno disponibili sul sito web dell'azienda.
Climb Bio (Nasdaq: CLYM) ha anunciado un evento virtual para inversores programado para el 15 de octubre de 2024. El evento contará con presentaciones de miembros clave del equipo directivo y un experto externo, proporcionando actualizaciones sobre la estrategia de la empresa y su enfoque en el desarrollo de terapias para enfermedades mediadas por el sistema inmunológico.
Los presentadores incluirán a Aoife Brennan (Presidenta y CEO), Stephen Thomas (Miembro de la Junta), Jan Hillson (Asesor Clínico Senior), Nishi Rampal (SVP de Desarrollo Clínico), Brett Kaplan (COO) y Frank Cortazar (Director del Centro de Nefrología, Vasculitis y Glomerular de Nueva York).
El evento ofrecerá una revisión detallada del principal activo de Climb Bio, budoprutug, un anticuerpo monoclonal anti-CD19 diseñado para tratar varias enfermedades mediadas por el sistema inmunológico. Budoprutug ha mostrado depleción de células B en los primeros ensayos clínicos. Una transmisión en vivo y una repetición estarán disponibles en el sitio web de la empresa.
클라임 바이오(Nasdaq: CLYM)는 가상 투자 행사를 2024년 10월 15일로 예정했다고 발표했습니다. 이 행사에서는 주요 경영진과 외부 전문가의 발표가 있을 예정이며, 회사의 전략과 면역 매개 질환 치료제 개발에 대한 집중 사항에 대한 업데이트를 제공할 것입니다.
발표자에는 Aoife Brennan(회장 겸 CEO), Stephen Thomas(이사), Jan Hillson(선임 임상 자문), Nishi Rampal(임상 개발 SVP), Brett Kaplan(COO) 및 Frank Cortazar(뉴욕 신장 혈관염 및 사구체 센터 소장)가 포함됩니다.
이번 행사는 클라임 바이오의 주요 자산인 부도프루투그에 대한 심층적인 리뷰를 제공할 것이며, 이는 다양한 면역 매개 질환을 치료하기 위해 설계된 항-CD19 단일클론 항체입니다. 부도프루투그는 초기 임상 시험에서 B세포 감소를 보여주었습니다. 생중계 및 재방송은 회사 웹사이트에서 제공될 예정입니다.
Climb Bio (Nasdaq: CLYM) a annoncé un événement virtuel pour les investisseurs prévu pour le 15 octobre 2024. L'événement comportera des présentations de membres clés de l'équipe de direction ainsi qu'un expert externe, fournissant des mises à jour sur la stratégie de l'entreprise et son orientation vers le développement de thérapies pour les maladies à médiation immunitaire.
Les présentateurs incluront Aoife Brennan (Présidente et CEO), Stephen Thomas (Membre du conseil), Jan Hillson (Conseiller clinique senior), Nishi Rampal (SVP du développement clinique), Brett Kaplan (COO) et Frank Cortazar (Directeur du Centre de néphrologie, vasculites et glomérules de New York).
L'événement proposera un examen approfondi du principal actif de Climb Bio, budoprutug, un anticorps monoclonal anti-CD19 conçu pour traiter diverses maladies à médiation immunitaire. Budoprutug a montré une déplétion des cellules B lors des premiers essais cliniques. Une diffusion en direct et un replay seront disponibles sur le site Web de l'entreprise.
Climb Bio (Nasdaq: CLYM) hat ein virtuelles Investoren-Event für den 15. Oktober 2024 angekündigt. Die Veranstaltung wird Präsentationen von wichtigen Mitgliedern des Managementteams und einem externen Experten umfassen und Updates zur Unternehmensstrategie sowie den Fokus auf die Entwicklung von Therapeutika für immunvermittelte Krankheiten bieten.
Zu den Präsentatoren gehören Aoife Brennan (Präsidentin und CEO), Stephen Thomas (Vorstandsmitglied), Jan Hillson (Senior Clinical Advisor), Nishi Rampal (SVP für klinische Entwicklung), Brett Kaplan (COO) und Frank Cortazar (Direktor des Nephrologie-, Vaskulitiden- und Glomerulus-Zentrums in New York).
Die Veranstaltung wird einen umfassenden Überblick über Climb Bios führendes Produkt budoprutug bieten, ein anti-CD19-Monoklonalantikörper, der zur Behandlung verschiedener immunvermittelter Krankheiten entwickelt wurde. Budoprutug hat in frühen klinischen Studien eine B-Zell-Depletion gezeigt. Ein Live-Streaming und eine Wiederholung werden auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
WELLESLEY, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will host a virtual investor day on October 15, 2024. The event will feature members of Climb Bio’s management team and an external expert who will provide an update to the investment community on the Company’s strategy and focus on developing therapeutics for immune-mediated diseases.
Climb Bio’s virtual investor event will include presentations from Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer, Stephen Thomas, Ph.D., Member of Climb Bio’s Board and Co-founder of Tenet Medicines, Jan Hillson, M.D., Senior Clinical Advisor, Nishi Rampal, M.D., Senior Vice President, Clinical Development, and Brett Kaplan, M.D., Chief Operating Officer as well as presentations from a key opinion leader, Frank Cortazar, Director of the New York Nephrology Vasculitis and Glomerular Center.
The event will provide an in-depth review of Climb Bio’s lead asset, budoprutug, an anti-CD19 monoclonal antibody that is designed to treat a broad range of immune-mediated diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy and has demonstrated B-cell depletion in early clinical trials.
Register for the event here.
A live webcast of the event, as well as a replay, will be available under "Events and Presentations" in the Investors section of the Company's website: climbbio.com
About Climb Bio, Inc.
Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit climbbio.com.
Investors
Chris Brinzey
ICR Westwicke
chris.brinzey@westwicke.com
339-970-2843
Media
Jon Yu
ICR Westwicke
jon.yu@westwicke.com
475-395-5375
FAQ
When is Climb Bio (CLYM) hosting its virtual investor event?
What will be discussed at Climb Bio's (CLYM) virtual investor event?
Who are the key presenters at Climb Bio's (CLYM) upcoming investor event?
What is budoprutug, Climb Bio's (CLYM) lead asset?
How can investors access Climb Bio's (CLYM) virtual investor event?
